OT: Distressing Shift in Pharma Thinking [7:09 pm]
A Cancer Drug Shows Promise, at a Price That Many Can’t Pay
Until now, drug makers have typically defended high prices by noting the cost of developing new medicines. But executives at Genentech and its majority owner, Roche, are now using a separate argument –— citing the inherent value of life-sustaining therapies.
Also known as “your money or your life” pricing.
Later: From the 2/17 NYTimes: Editorial: Price Gouging on Cancer Drugs?

